IRLAB provides additional efficacy data from the Phase IIb study of pirepemat in patients with Parkinson’s disease
Gothenburg, Sweden, March 28, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson’s disease, today announces further results based on prespecified in-depth efficacy analyses of the data generated in the Phase IIb dose finding and efficacy study of pirepemat (REACT-PD). The analysis reveals that in a medium plasma concentration range, pirepemat reduced the fall rate by as much as 51.5% after three months of treatment. This effect is highly clinically meaningful and statistically significant (p<0.05 vs. placebo). Based on these compelling results, the company now continues with further analyses of the study data to reach a decision on how to best design forthcoming studies during the continued clinical development of the drug candidate.
Read More >Watch IRLAB’s
Capital Markets Day 2023!
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.
Presentation at Redeye’s Theme Event Neurology
Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.
Read More >